Centogene

146 articles with Centogene

• CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

  5/23/2022

  Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, as part of a consortium of organizations in genetics, announced the release of updated recommendations for Whole Genome Sequencing in the rare disease diagnostic setting.

• CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

  5/19/2022

  Centogene N.V. announced that Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites investors to participate via virtual one-on-one meetings.

• CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

  4/28/2022

  Centogene N.V. announced it has extended its partnership with Takeda to diagnose patients with rare metabolic and rare neurodegenerative diseases.

• CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results

  3/30/2022

  Centogene N.V. today announced financial results for the fourth quarter and fiscal year ended December 31, 2021, and provided a business update.

• CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference

  3/24/2022

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that CEO Kim Stratton will speak at the sixteenth annual BIO-Europe Spring conference on March 31, 2022, at 3:00 p.m. CEST/9:00 a.m. EDT.

• CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022

  3/23/2022

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it will issue its financial results for the quarter and full year ended December 31, 2021, on Wednesday, March 30, 2022, and will host a conference call and webcast to discuss these results at 2 p.m. CEST / 8 a.m. EDT.

• CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer

  3/17/2022

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced an expansion of the Company’s data access and collaboration agreement with Pfizer Inc.

• CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

  2/8/2022

  Centogene N.V. today announced plans for the transition of Chief Financial Officer René Just and the appointment of Miguel Coego Rios as Executive Vice President of Finance & Legal and Interim CFO. René Just has resigned from the Company effective March 31, 2022.

• CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan

  2/1/2022

  Centogene N.V. announced the closing of a EUR 15 million private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures, as well as the entry into a USD 45 million senior secured loan facility provided by Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare companies.

• CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer

  2/1/2022

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the Company’s Supervisory Board’s nomination of Kim Stratton as Chief Executive Officer, transitioning from her prior designation as Interim CEO.

• CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

  2/1/2022

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next General Meeting.

• CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development

  1/20/2022

  Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand and treat rare diseases, and Insilico Medicine, an end-to-end Artificial Intelligence (AI) -driven drug discovery company, today announced a research and development collaboration to accelerate the discovery of novel therapeutic targets for Niemann-Pick disease type C.

• CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World

  1/4/2022

  Centogene N.V. announced the global release of CentoCloud, a SaaS platform enabling decentralized analysis, interpretation, and reporting of genomic variants linked to rare diseases.

• CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery

  12/23/2021

  Centogene N.V. today announced that it has been awarded the Health-i Award, which recognizes companies that are transforming healthcare in Germany and beyond.

• CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO

  12/20/2021

  Centogene N.V. announced that its Chief Executive Officer, Andrin Oswald, M.D., is taking a temporary medical leave of absence for a period of at least four weeks.

• CENTOGENE Reports Third Quarter 2021 Financial Results

  11/24/2021

  Centogene N.V. today announced financial results for the third quarter ended September 30, 2021, and provided a recent business update.

• CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

  11/18/2021

  Centogene N.V. today announced that it will issue its financial results for the quarter ended September 30, 2021, on Wednesday, November 24, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CET / 8 a.m. ET that day.

• CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

  11/4/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that it has expanded its partnership with Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study

  10/28/2021

  Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced that the first patient has been enrolled in the international EFRONT Study, an observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia.